At the end of 2023, National Healthcare Security Administration announced the results of the adjustment of NRDL (The National Reimbursement Drug List, NRDL was introduced in 2000 to support medical healthcare and providing patients with basic medical treatments.), there are 126 drugs newly added. Jiudian Pharmaceutical's exclusive dosage form Ketoprofen Cataplasms is one of them. The new NRDL will be officially implemented on January 1, 2024.

At this point, Jiudian have 60 varieties and 74 specifications on NRDL.

Ketoprofen Cataplasms was on the Market at the end of Feb, 2023, and on NRDL after 10 months. It reflects the recognition and attention of all sectors of society for external use of non-steroidal anti-inflammatory drugs. 

This help Jiudian Pharmaceutical’s Ketoprofen Cataplasms market grow rapidly.